Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals operates with a strong liquidity position, as evidenced by a current ratio of 24.53, indicating that its current assets significantly exceed its current liabilities. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. However, its operating cash flow is negative at -$6.35 million, reflecting the typical cash burn of a clinical-stage biotechnology firm. Profitability metrics are negative, with a return on equity of -72.78% and a return on assets of -69.86%. These figures are in line with the typical performance of early-stage biotechnology firms, which often prioritize R&D over profitability. The company has not yet generated revenue and reported a net loss of -$8.48 million in the latest period. Anebulo's business is concentrated in a single therapeutic area—cannabis toxicity treatments—with its lead candidate, selonabant, in development. The company has not disclosed geographic revenue breakdowns, but its operations are likely centered in the United States, given the regulatory focus on cannabis-related conditions in that market. The company's growth trajectory is speculative, as it has not yet commercialized any products. Analysts have recorded a last actual EPS of -$0.25 and zero revenue, indicating that the company is in the early stages of development. The outlook for the next fiscal year remains uncertain, as the company has not provided specific guidance. Risk factors include the typical challenges of a clinical-stage biotechnology firm, such as regulatory hurdles, clinical trial outcomes, and the high cost of drug development. The company has not disclosed any immediate dilution risks, with both basic and diluted shares outstanding at 40.78 million. However, the absence of revenue and the need for continued R&D funding could lead to future equity issuances. Recent events include the continued development of selonabant, with a focus on both oral and intravenous formulations. The company has not disclosed any recent filings or transcripts that would indicate significant changes in strategy or operations.